Posted by Michael Wonder on 12 Sep 2022
BioLineRx announces submission of new drug application to FDA for motixafortide in stem cell mobilisation
12 September 2022 - Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 trial.
BioLineRx today announced that the Company has submitted its new drug application to the US FDA for motixafortide in stem cell mobilisation for autologous bone marrow transplantation for multiple myeloma patients.
